News - Gastro-intestinals, vedolizumab

Filter

Popular Filters

Takeda's vedolizumab enters Ph III in Japan for UC and Crohn's disease

Takeda's vedolizumab enters Ph III in Japan for UC and Crohn's disease

08-01-2014

Japan’s largest drugmaker Takeda Pharmaceutical revealed today that vedolizumab), an investigational…

Asia-PacificGastro-intestinalsPharmaceuticalResearchTakeda Pharmaceuticalsvedolizumab

Takeda stops development of diabetes candidate fasiglifam; PDUFA date for vedolizumab extended

Takeda stops development of diabetes candidate fasiglifam; PDUFA date for vedolizumab extended

27-12-2013

Japan’s largest drugmaker Takeda Pharmaceutical has decided voluntarily to terminate the development…

DiabetesfasiglifamGastro-intestinalsNorth AmericaPharmaceuticalRegulationResearchTakeda PharmaceuticalsUSAvedolizumab

FDA advisory panel backs approval of Takeda’s vedolizumab

FDA advisory panel backs approval of Takeda’s vedolizumab

10-12-2013

A US Food and Drug Administration advisory committee has recommended approval of vedolizumab from Japan’s…

Gastro-intestinalsPharmaceuticalRegulationTakeda PharmaceuticalsUSAvedolizumab

US Priority Review for Takeda's vedolizumab for ulcerative colitis

05-09-2013

Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502) says that the US Food and Drug Administration…

Gastro-intestinalsNorth AmericaPharmaceuticalRegulationTakeda Pharmaceuticalsvedolizumab

Takeda's vedolizumab shows efficacy in colitis and Crohn's disease

22-08-2013

A new investigational antibody - vedolizumab - from Japan's largest drugmaker, Takeda Pharmaceuticals…

Gastro-intestinalsPharmaceuticalResearchTakeda Pharmaceuticalsvedolizumab

Takeda files BLA for vedolizumab for Crohn's and ulcerative colitis in USA

21-06-2013

The US subsidiary of Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) has submitted a Biologics…

Gastro-intestinalsNorth AmericaPharmaceuticalRegulationTakeda Pharmaceuticalsvedolizumab

Vedolizumab has potential to offer improvement over infliximab in UC

30-04-2013

Surveyed US and EU5 gastroenterologists agree that new moderate to severe ulcerative colitis (UC) therapies…

EuropeGastro-intestinalsinfliximabJanssenMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRemicadeTakeda Pharmaceuticalsvedolizumab

Eisai slams German decision on Fycompa; Takeda files vedolizumab with EMA

08-03-2013

The German Federal Joint Committee (G-BA), the decision-making body of the self-governing medical system…

EisaiEuropeFycompaGastro-intestinalsNeurologicalPharmaceuticalRegulationTakeda Pharmaceuticalsvedolizumab

US gastroenterologists' attitudes to prescribing for Crohn's disease and ulcerative colitis

09-09-2012

When evaluating the most important attributes for emerging therapies for Crohn's disease (CD) and ulcerative…

BiotechnologyGastro-intestinalsHumiraMarkets & MarketingNorth AmericaRemicadeSimponi Injectionvedolizumab

Takeda's vedolizumab meets primary endpoints in Ph III Crohn's disease study

13-05-2012

Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) has reported positive top-line results from…

Gastro-intestinalsPharmaceuticalResearchTakeda Pharmaceuticalsvedolizumab

Ulcerative colitis drug market to reach $3 billion by 2020

02-05-2012

The ulcerative colitis drug market will experience moderate growth over the next decade, increasing from…

Gastro-intestinalsHumiraMarkets & MarketingPharmaceuticalRemicadeSimponi Injectiontofacitinibvedolizumab

Back to top